Literature DB >> 12113123

Mismatch repair defects as a cause of resistance to cytotoxic drugs.

J A Irving1, A G Hall.   

Abstract

In this short review, we aim to bring together the most recent evidence implicating mismatch repair pathway defects as a cause of drug resistance to a spectrum of chemotherapeutic agents in a variety of cancers. Experimental and clinical studies are discussed and possible strategies that may be employed to overcome the multidrug resistant phenotype afforded by such defects.

Entities:  

Mesh：

Year:  2001        PMID： 12113123     DOI： 10.1586/14737140.1.1.149

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  11 in total

Review 1.  Gender specific tumour pharmacology--from kinetics to genetics.

Authors:  Robert M Mader
Journal:  Wien Med Wochenschr       Date:  2006-10

2.  Small molecule induction of MSH2-dependent cell death suggests a vital role of mismatch repair proteins in cell death.

Authors:  Aksana Vasilyeva; Jill E Clodfelter; Brian Rector; Thomas Hollis; Karin D Scarpinato; Freddie R Salsbury
Journal:  DNA Repair (Amst)       Date:  2008-11-12

Review 3.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

4.  Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry.

Authors:  Joanna Will; William S Sheldrick; Dirk Wolters
Journal:  J Biol Inorg Chem       Date:  2007-12-22       Impact factor: 3.358

5.  Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation.

Authors:  L Mannarini; G Bertino; P Morbini; C Villa; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

6.  Parameters of Reserpine Analogs That Induce MSH2/MSH6-Dependent Cytotoxic Response.

Authors:  Aksana Vasilyeva; Jill E Clodfelter; Michael J Gorczynski; Anthony R Gerardi; S Bruce King; Freddie Salsbury; Karin D Scarpinato
Journal:  J Nucleic Acids       Date:  2010-09-13

7.  Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells.

Authors:  Tao Yan; Yuji Seo; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response.

Authors:  Freddie R Salsbury; Jill E Clodfelter; Michael B Gentry; Thomas Hollis; Karin Drotschmann Scarpinato
Journal:  Nucleic Acids Res       Date:  2006-04-28       Impact factor: 16.971

9.  Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention.

Authors:  Antonella Di Sotto; Silvia Di Giacomo; Elisabetta Rubini; Alberto Macone; Marco Gulli; Caterina Loredana Mammola; Margherita Eufemi; Romina Mancinelli; Gabriela Mazzanti
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

10.  Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.

Authors:  Sofia Sagredou; Panagiotis Dalezis; Eirini Papadopoulou; Maria Voura; Maria V Deligiorgi; Michail Nikolaou; Mihalis I Panayiotidis; George Nasioulas; Vasiliki Sarli; Dimitrios T Trafalis
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.